HCPLive Network

Collagenase Clostridium Histolyticum Tolerable in Peyronie's Disease

FRIDAY, April 26 (HealthDay News) -- For patients with Peyronie's disease, treatment with collagenase clostridium histolyticum (CCH) intralesional injections is efficacious and tolerable, according to research published online Feb. 1 in The Journal of Urology.

Martin Gelbard, MD, from the Urology Associates Medical Group, in Burbank, CA, and colleagues examined the clinical efficacy and safety of CCH intralesional injections among patients with Peyronie's disease (417 and 415 patients in Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies [IMPRESS] I and II, respectively). CCH injections were given through a maximum of four treatment cycles, each separated by six weeks, with two injections per cycle.

Based on meta-analysis of data from the two studies, the researchers found that patients treated with CCH experienced a mean 34 percent improvement in penile curvature deformity, compared with a mean 18.2 percent improvement seen in placebo-treated individuals (P < 0.0001). In CCH-treated versus placebo-treated individuals, the mean change in Peyronie's disease bother score was significantly improved. There were three corporal rupture serious adverse events, all of which were repaired surgically.

"The IMPRESS I and II studies support the clinical efficacy and safety of CCH treatment for both the physical and psychological aspects of Peyronie's disease," the authors write.

Several authors disclosed financial ties to Auxilium Pharmaceuticals, which funded the study and manufactures and markets CCH.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
The US Food and Drug Administration (FDA) has approved Xiaflex (collagenase clostridium histolyticum) as the first non-surgical treatment for Peyronie’s disease.
The burden and threats posed by antibiotic resistance infections are discussed in a report published by the U.S. Centers for Disease Control and Prevention.
The likelihood of unplanned admission is increased with polypharmacy, but the association is modified by the number of long-term conditions, according to a study published online Jan. 16 in the British Journal of Clinical Pharmacology.
The American Medical Association has released resources to help doctors confront policy jumpers who may pose a financial risk to physicians during the Affordable Care Act's 90-day premium grace period, according to an article published March 25 in Medical Economics.
Stethoscopes get contaminated after a single physical exam, with the contamination greater than that seen on most of the physician's dominant hand, barring the fingertips, according to a study published online Feb. 27 in the Mayo Clinic Proceedings.
For patients with kidney transplants, a urine test could detect dysfunction easier than by invasive measures, according to a study published in the March issue of the Journal of the American Society of Nephrology.
There were an estimated 648,000 patients with 721,800 health care-associated infections in U.S. acute care hospitals in 2011, according to research published in the March 27 issue of the New England Journal of Medicine.
More Reading